Jesus F San-Miguel
Overview
Explore the profile of Jesus F San-Miguel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
4485
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ocio E, Perrot A, Bories P, San-Miguel J, Blau I, Karlin L, et al.
Leukemia
. 2023 Jun;
37(7):1521-1529.
PMID: 37316728
Patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplantation (ASCT) have lower survival rates and may benefit from frontline regimens that include novel agents. This Phase...
12.
Garcia-Sanz R, Varettoni M, Jimenez C, Ferrero S, Poulain S, San-Miguel J, et al.
Semin Hematol
. 2023 Apr;
60(2):90-96.
PMID: 37099028
Apart from the MYD88 mutation, extensive information exists on the molecular mechanisms in Waldenström's Macroglobulinemia and its potential utility in the diagnosis and treatment tailoring. However, no consensus recommendations are...
13.
Simoes C, Villar S, Ariceta B, Garces J, Burgos L, Alignani D, et al.
Br J Haematol
. 2023 Apr;
201(6):1239-1244.
PMID: 37057357
No abstract available.
14.
Burgos L, Tamariz-Amador L, Puig N, Cedena M, Guerrero C, Jelinek T, et al.
J Clin Oncol
. 2023 Mar;
41(16):3019-3031.
PMID: 36930848
Purpose: The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present with a monoclonal gammopathy of undetermined significance (MGUS)-like phenotype has been hypothesized, but methods to...
15.
Rodriguez-Otero P, San-Miguel J
Hematology Am Soc Hematol Educ Program
. 2022 Dec;
2022(1):180-189.
PMID: 36485132
Despite significant improvement in the treatment of multiple myeloma (MM), a cure remains elusive, and patients failing proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies remain a challenge due to...
16.
Schjesvold F, Paiva B, Ribrag V, Rodriguez-Otero P, San-Miguel J, Robak P, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Nov;
23(1):e59-e70.
PMID: 36450626
Introduction: Mitogen-activated protein kinase pathway mutations are present in >50% of patients with relapsed/refractory (R/R) multiple myeloma (MM). MEK inhibitors show limited single-agent activity in R/R MM; combination with B-cell...
17.
Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Sithara A, Pospisilova L, et al.
J Clin Oncol
. 2022 Oct;
41(7):1383-1392.
PMID: 36315921
Purpose: Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased...
18.
Rosa-Rosa J, Cuenca I, Medina A, Vazquez I, Sanchez-delaCruz A, Buenache N, et al.
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291952
Next-generation sequencing (NGS) has greatly improved our ability to detect the genomic aberrations occurring in multiple myeloma (MM); however, its transfer to routine clinical labs and its validation in clinical...
19.
Simoes C, Chillon M, Martinez-Cuadron D, Calasanz M, Vridiales M, Vazquez I, et al.
Blood Adv
. 2022 Oct;
7(1):167-173.
PMID: 36240453
Clonal evolution in acute myeloid leukemia (AML) originates long before diagnosis and is a dynamic process that may affect survival. However, it remains uninvestigated during routine diagnostic workups. We hypothesized...
20.
Rodriguez-Otero P, San-Miguel J
Lancet Haematol
. 2022 Oct;
9(11):e799-e801.
PMID: 36209763
No abstract available.